H.C. Wainwright Further Expands Its Biotechnology Practice with Four Senior Level Hires

  H.C. Wainwright Further Expands Its Biotechnology Practice with Four Senior
  Level Hires

Business Wire

NEW YORK -- June 20, 2014

H.C. Wainwright & Co., LLC (“HCW”) announced today the addition of one
Managing Director in Equity Research and three Vice Presidents in Investment
Banking to further enhance its Biotechnology Practice.

Swayampakula Ramakanth (“RK”), PhD. joins HCW in Equity Research as Managing
Director, Senior Biotechnology Analyst. Prior to joining HCW, Dr. Ramakanth
was a Junior Analyst at Jefferies and Merrill Lynch covering large cap
pharmaceuticals, and at First Albany and Rodman & Renshaw covering
biotechnology companies. Dr. Ramakanth previously conducted bench research at
Regeneron Pharmaceuticals, Inc. and directed a preclinical drug development
group. Dr. Ramakanth’s expertise consists of companies in the oncology,
infectious diseases, metabolic disorders and animal health sectors. Dr.
Ramakanth has over 10 years of experience as a life sciences equity analyst
and 7 years of biotechnology industry experience.

Aileen M. Gibbons, PhD., Sean W. Hagerty, PhD. and Jeffery R. Smith, PhD. join
the HCW Healthcare Investment Banking team as Vice Presidents. Dr. Gibbons
earned her doctorate in liposomal formulation of protease inhibitor proteins
to treat inflammatory lung diseases from the Royal College of Surgeons in
Ireland. Dr. Hagerty earned his doctorate in Cellular and Molecular Biology
from NYU School of Medicine by characterizing the role of TORC1 in Schwann
cell dedifferentiation. Dr. Smith earned his doctorate in Cancer Biology from
the Gerstner Sloan-Kettering Graduate School of Biomedical Sciences
investigating the role of Rho GTPases in cytoskeletal remodeling during breast
cancer proliferation and metastasis.

“We are pleased that RK, Aileen, Sean and Jeff have decided to join HCW to
further grow our biotechnology franchise,” commented Mark Viklund, Chief
Executive Officer of HCW. “RK joins Ren Benjamin, PhD. and Andrew Fein in
Biotechnology Equity Research to enhance HCW’s goal of providing insightful
investment ideas to our institutional investor clientele. The addition of
Aileen, Sean and Jeff to our investment banking practice will enable HCW to
deliver differentiated capital markets advice to our biotechnology clients
given their significant scientific achievements in their fields of study.”

About H.C. Wainwright & Co., LLC

H.C. Wainwright & Co., LLC is an investment bank dedicated to providing
corporate finance, strategic advisory and related services to public and
private growth companies across multiple sectors and regions. The H.C.
Wainwright team has been the leader in the PIPE (private investment in public
equity) and RD (registered direct offering) transaction markets. H.C.
Wainwright was established in 1868 and is headquartered in New York City.


H.C. Wainwright & Co., LLC
Edward Silvera, 212-356-0500
Press spacebar to pause and continue. Press esc to stop.